Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human steps as China's Decree 818 raises the pace.
|Articles|August 23, 2019
Details Make the Difference for Successful Disinfection
Author(s)Contec, Inc.
Disinfection is not just about the disinfectant. The details, tools and protocols implemented in a facility determine if a disinfection program is successful. This paper reviews the details that are often overlooked but can make a big difference.
Related to this article
The deadline to comment on FDA's generative AI paper is Oct 19, 2026. We explain why professionals in pharma manufacturing should weigh in.
The FDA expanded Anktiva to BCG-unresponsive papillary-only NMIBC using existing CIS trial data, a precedent with implications for development timelines and supply planning.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
Ishani Maharaj of Ingredients + Specialties from Univar Solutions explains how to stabilize GLP-1 multi-agonists, weigh delivery formats, and qualify novel excipients and suppliers.
MASH and cardiomyopathy AI collaboration: AstraZeneca pays insitro $40M upfront for target discovery, then leads clinical development and CMC planning.
Boyang Wang, Immortal Dragons, discusses how the FDA’s Expedited IND Pilot must prove efficiency as sponsors chase the fastest route to valid first-in-human data.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
Trending on Pharmaceutical Technology
1
Formulation Strategies for Next-Generation Multiagonists
2
PharmTech AI Pulse Check: Why Pharma Should Weigh In on FDA's Generative AI Paper
3
First-in-Human Trial Speed: Why FDA Trails China
4
MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI
5